Neurocrine Biosciences Inc
XBER:NB3
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
N
|
Neurocrine Biosciences Inc
XBER:NB3
|
US |
|
Sands China Ltd
F:599A
|
MO |
|
Citius Pharmaceuticals Inc
F:47N
|
US |
|
B
|
Bank of China Ltd
XMUN:W8V
|
CN |
|
H
|
HeidelbergCement AG
XHAM:HEI
|
DE |
Wall St Price Targets
NB3 Price Targets Summary
Neurocrine Biosciences Inc
According to Wall Street analysts, the average 1-year price target for NB3 is 142.63 EUR with a low forecast of 108.15 EUR and a high forecast of 192.07 EUR.
Price Targets
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.
What is NB3's stock price target?
Price Target
142.63
EUR
According to Wall Street analysts, the average 1-year price target for NB3 is 142.63 EUR with a low forecast of 108.15 EUR and a high forecast of 192.07 EUR.
What is the Revenue forecast for Neurocrine Biosciences Inc?
Projected CAGR
9%
Over the last 13 years, the compound annual growth rate for Revenue has been 36%. The projected CAGR for the next 8 years is 9%.
What is the Operating Income forecast for Neurocrine Biosciences Inc?
Projected CAGR
30%
Over the last 13 years, the compound annual growth rate for Operating Income has been 53%. The projected CAGR for the next 8 years is 30%.
What is the Net Income forecast for Neurocrine Biosciences Inc?
Projected CAGR
18%
Over the last 13 years, the compound annual growth rate for Net Income has been 42%. The projected CAGR for the next 8 years is 18%.
